immunotherapy / CD4+ Cancer Research Results

immuno, immunotherapy: Click to Expand ⟱

Features:

Immunotherapy is not one drug class. It includes:
-Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
-CAR-T therapies
-Monoclonal antibodies
-Cytokine therapies (IL-2, IFN-α)
-Cancer vaccines
-Bispecific T-cell engagers

PD-1 blockade antibody therapy is one of the cornerstone approaches in modern cancer immunotherapy.
Under normal physiological conditions, when PD-1 binds to its ligands (PD-L1 or PD-L2) on other cells, it functions as a "checkpoint" to reduce overly active T cell responses and prevent autoimmunity.
PD-1 blockade therapies involve monoclonal antibodies that target either PD-1 or its ligand PD-L1.
• By blocking the interaction between PD-1 and its ligands, these antibodies effectively release the "brakes" on T cells.
• The re-activated T cells can then recognize and destroy cancer cells more efficiently.

Immunotherapy Class	Example Agents	Primary Target	Core Mechanism	Interaction Considerations	Net Effect
PD-1 inhibitors	Nivolumab, Pembrolizumab	PD-1 receptor on T cells	Blocks inhibitory PD-1 signaling → restores cytotoxic T-cell activity	High-dose steroids or strong immunosuppressants may blunt effect; autoimmune risk	↑ Anti-tumor immune activation
PD-L1 inhibitors	Atezolizumab, Durvalumab	PD-L1 on tumor/immune cells	Prevents PD-L1 from engaging PD-1 → enhances T-cell response	Similar immune-related adverse event (irAE) profile as PD-1 inhibitors	↑ Immune activation
CTLA-4 inhibitors	Ipilimumab	CTLA-4 checkpoint	Enhances early T-cell priming in lymph nodes	Higher autoimmune toxicity risk vs PD-1 class	↑ T-cell priming
CAR-T therapy	CD19 CAR-T products	Tumor antigen (e.g., CD19)	Genetically engineered T cells directly target tumor cells	Risk of cytokine release syndrome (CRS) and neurotoxicity	Direct immune-mediated tumor killing
Monoclonal antibodies (non-checkpoint)	Trastuzumab, Rituximab	Specific tumor antigens	Antibody-dependent cellular cytotoxicity (ADCC) or receptor blockade	Combination with chemo common; immune activation depends on Fc engagement	Targeted immune-mediated killing
Cytokine therapy	IL-2, IFN-α	Immune activation pathways	Stimulates T-cell and NK cell proliferation	High systemic toxicity; rarely used now vs checkpoint inhibitors	Broad immune stimulation
Cancer vaccines	mRNA or peptide-based	Tumor antigens	Induces tumor-specific immune memory	Often combined with checkpoint blockade	Adaptive immune priming
Bispecific T-cell engagers	Blinatumomab	CD3 + tumor antigen	Bridges T cells directly to tumor cells	CRS risk; continuous infusion in some protocols	Direct T-cell redirection

CD4+, CD4+ T Cells: Click to Expand ⟱

Source:

Type:

CD4+ T cells are T lymphocytes that express T cell receptors (TCRs).
Majority of cancer immunotherapies focus on harnessing the anti-tumour CD8+ cytotoxic T cell response, the potential role of CD4+ ‘helper’ T cells has largely remained in the background. multifaceted role of CD4+ T cells in the anti-tumour immune response.
CD4+ T cells play a critical role in developing and sustaining effective anti-tumour immunity, even in cancer immunotherapies specifically designed to activate a CD8+ CTL response.

Scientific Papers found: Click to Expand⟱

542-

Akk,

immuno,

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

CD4+↑, CXCc↑, PD-1↝,

1205-

Caff,

immuno,

Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody

in-vivo,

Melanoma,

B16-F10

OS↑, CD4+↑, CD8+↑, AntiTum↑, TNF-α↑, IFN-γ↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

Immune & Inflammatory Signaling ⓘ

CD4+↑, 2, CXCc↑, 1, IFN-γ↑, 1, PD-1↝, 1, TNF-α↑, 1,

Functional Outcomes ⓘ

AntiTum↑, 1, OS↑, 1,

Infection & Microbiome ⓘ

CD8+↑, 1,
Total Targets: 8

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: CD4+, CD4+ T Cells

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells